Zenas BioPharma Files 8-K on Operations and Financials
Ticker: ZBIO · Form: 8-K · Filed: Nov 12, 2024 · CIK: 1953926
Sentiment: neutral
Topics: operations, financials, disclosure
TL;DR
Zenas BioPharma dropped an 8-K on Nov 12th covering ops & financials. Check it.
AI Summary
Zenas BioPharma, Inc. filed an 8-K on November 12, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Waltham, MA.
Why It Matters
This 8-K filing provides an update on Zenas BioPharma's operational and financial status, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of operational and financial information, not indicating any immediate or significant risk.
Key Players & Entities
- Zenas BioPharma, Inc. (company) — Registrant
- November 12, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Waltham, MA (location) — Address of principal executive offices
- 001-42270 (commission_file_number) — SEC File Number
FAQ
What specific financial information is being reported in this 8-K?
The 8-K indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details are not provided in the provided text.
When was the earliest event reported in this filing?
The earliest event reported is November 12, 2024.
What is Zenas BioPharma's state of incorporation?
Zenas BioPharma, Inc. is incorporated in Delaware.
Where are Zenas BioPharma's principal executive offices located?
The principal executive offices are located at 1000 Winter Street, Suite 1200, Waltham, MA 02451.
What is the SEC file number for Zenas BioPharma?
The SEC file number for Zenas BioPharma, Inc. is 001-42270.
Filing Stats: 520 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-11-12 07:17:37
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ZBIO The Nasdaq Global Se
Filing Documents
- tm2427736d1_8k.htm (8-K) — 30KB
- tm2427736d1_ex99-1.htm (EX-99.1) — 51KB
- tm2427736d_ex99-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-24-116346.txt ( ) — 267KB
- zbio-20241112.xsd (EX-101.SCH) — 3KB
- zbio-20241112_lab.xml (EX-101.LAB) — 33KB
- zbio-20241112_pre.xml (EX-101.PRE) — 22KB
- tm2427736d1_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On November 12, 2024, Zenas BioPharma, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on November 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENAS BIOPHARMA, INC. By: /s/ Jennifer Fox Name: Jennifer Fox Title: Chief Business Officer and Chief Financial Officer Date: November 12, 2024